Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Medimarker's Laboratories

Pharmaceutical manufacturer · Pakistan

Pakistan pharmaceutical manufacturer represented in the DRAP PharmaPrice source with DML-linked registered products.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date27 Jul 2026Newest effective date among published current price records
Corporate profile evidence1 sourceCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Corporate source details checked
16 Aug 2026
Corporate profile completeness
38%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000615 Medimarker's Pharmaceuticals (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000615 74 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Profile Source Url source ↗
Location intelligence

Company location

Google Maps
Exact site not yet sourced

No exact premises location is published without a defensible source.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx77public portfolio records represented
REG73unique registrations represented
IDX75indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+2registry-only registrations
VER0registry-verified exact registrations
PKR71current validated price records
G36generic molecules in indexed catalogue
DF10dosage-form groups
TA9therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage92%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage97%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMedimarker's LaboratoriesShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medimarkers-laboratoriesGenerated 23 Sep 2026Anti-infectives48 · 64%Pain & musculoskeletal6 · 8%Vitamins, minerals & nutrition5 · 7%Respiratory & allergy5 · 7%Fluids & supportive care5 · 7%Cardiovascular2 · 3%CNS & mental health2 · 3%Other therapeutic areas2 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMedimarker's LaboratoriesDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medimarkers-laboratoriesGenerated 23 Sep 202675presentationsTablet23 · 31%Injection19 · 25%Suspension8 · 11%Capsule6 · 8%Infusion6 · 8%Syrup5 · 7%Other forms8 · 11%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionMedimarker's LaboratoriesCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medimarkers-laboratoriesGenerated 23 Sep 202669comparable productsBelow peer median25 · 36%Near peer median25 · 36%Above peer median19 · 28%Company median price position-0.5%Lowest-price equivalents9Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMedimarker's LaboratoriesCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medimarkers-laboratoriesGenerated 23 Sep 2026Mediate Pharmaceutical Pvt Ltd29 shared81% overlapS.J & G. Fazul Ellahie (pvt) limite…25 shared69% overlapPulse Pharmaceuticals (Pvt.) Ltd.25 shared69% overlapPharmasol (Pvt) Ltd.24 shared67% overlapZafa Pharmaceutical Laboratories (P…24 shared67% overlapBarrett Hodgson Pakistan (Pvt.) Ltd24 shared67% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives48 products · 64%
Pain & musculoskeletal6 products · 8%
Vitamins, minerals & nutrition5 products · 7%
Respiratory & allergy5 products · 7%
Fluids & supportive care5 products · 7%
Cardiovascular2 products · 3%
CNS & mental health2 products · 3%
Hematology & thrombosis1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins12 products · 16%
Fluoroquinolone antibacterials12 products · 16%
Analgesics / NSAIDs6 products · 8%
Macrolide antibacterials5 products · 7%
Vitamins / minerals / hematinics5 products · 7%
Fluids, electrolytes & diluents5 products · 7%
Second-generation cephalosporins5 products · 7%
Penicillin antibacterials4 products · 5%
Formulation footprint

Dosage forms

Tablet23 products
Injection19 products
Suspension8 products
Capsule6 products
Infusion6 products
Syrup5 products
Cream3 products
Drops3 products
Sachet1 products
Solution1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CefmarkCeftriaxone 5presentations 1 g, 250 mg, 500 mg · Injection #2 RoxlitCefuroxime 5presentations 1.5 g, 250 mg, 250 mg/5 mL, 750 mg · Infusion, Injection, Suspension #3 MoxilabMoxifloxacin 4presentations 0.5%, 400 mg · Drops, Infusion, Tablet #4 PotradolParacetamol 4presentations 1000 mg/100 mL, 120 mg/5 mL, 250 mg/5 mL, 500 mg · Infusion, Syrup, Tablet #5 AmoxicillinAmoxicillin 3presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL · Suspension, Capsule #6 C-MarkerClarithromycin 3presentations 125 mg/5 mL, 250 mg, 500 mg · Syrup, Tablet
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2536% of comparable products
Near market median25within ±5% of median
Above market median1928% of comparable products
Lowest-price equivalents9ties included
Company median price position -0.5% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Roxlit 1.5 gCefuroxime · Dry powder for injection · 1's PKR 192.12/vial/unit-42.6% vs market median Roxlit 750 mgCefuroxime · Dry powder for injection · 1's PKR 115.84/vial/unit-40.3% vs market median Med-Lecal 5ml 5 mgCholecalciferol · Injection · 1mlx5's(Ampoule) PKR 112.36/mL-39.9% vs market median Markonza 2 %Miconazole · Cream · 20gm PKR 4.80/g-37.4% vs market median Liv-Mark 500 mg/100 mLLevofloxacin · IV infusion · 100ml vial PKR 4.62/mL-31.7% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 29shared generics S.J & G. Fazul Ellahie (pvt) limited.193 products · 68 generics 25shared generics Pulse Pharmaceuticals (Pvt.) Ltd.116 products · 48 generics 25shared generics Pharmasol (Pvt) Ltd.257 products · 102 generics 24shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 24shared generics Barrett Hodgson Pakistan (Pvt.) Ltd187 products · 63 generics 24shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers71Distinct registrations among indexed, published, presentation-validated products only
Verified price observations75
Products with a verified price75
Products with multiple price observations0
Source records with multiple versions73
Latest portfolio source check22 Sep 2026
Latest effective price date27 Jul 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

73 unique registration(s) · 75 indexed presentation(s) · 2 registry-only registration(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Amoxicillin Amoxicillin 125 mg/5 mL Dry suspension 60ml 050602 PKR 91.49 PKR 1.52/mL 7% above median
Amoxicillin Amoxicillin 250 mg/5 mL Dry suspension 60ml 050603 PKR 134.34 PKR 2.24/mL 7% above median
Amoxicillin Amoxicillin 250 mg Capsule 100's 050604 PKR 1,129.16 PKR 11.29/capsule Near median
Amoxicillin Amoxicillin + Flucloxacillin 250 mg + 250 mg Capsule 100's 050605 PKR 1,995.43 PKR 19.95/capsule 47% above median
Artefanker Artemether + Lumefantrine 20 mg + 120 mg Tablet 16's 047479 PKR 502.27 PKR 31.39/tablet 21% below median
Artirial Artemether 80 mg Injection 1mlx5's ampoules 100404 PKR 886.36 — No comparator
Azi-Mark Azithromycin 250 mg Tablet 10's 047081 PKR 350.85 PKR 35.09/tablet 25% below median
Azomarker Dry Azithromycin 200 mg/5 mL Syrup 15ml 047068 PKR 304.69 PKR 20.31/mL No comparator
C-Mark Cefixime 200 mg Capsule 5's 098922 PKR 360.08 PKR 72.02/capsule 15% above median
C-Mark Dry Cefixime 100 mg/5 mL Dry suspension 30ml 100395 PKR 314.24 PKR 10.47/mL Near median
C-Mark Dry Cefixime 200 mg/5 mL Dry suspension 30ml 100396 PKR 384.56 PKR 12.82/mL Near median
C-Marker Clarithromycin 125 mg/5 mL Syrup 60ml 047069 PKR 411.79 PKR 6.86/mL 11% below median
C-Marker Clarithromycin 250 mg Tablet 10's 047082 PKR 443.18 PKR 44.32/tablet 7% below median
C-Marker Clarithromycin 500 mg Tablet 10's 047083 PKR 821.73 PKR 82.17/tablet Near median
Cefmark Ceftriaxone 250 mg Injection 1's 100387 PKR 186.51 PKR 186.51/vial/unit Near median
Cefmark Ceftriaxone 1 g Injection 1's 100388 PKR 592.75 PKR 592.75/vial/unit Near median
Cefmark Ceftriaxone 250 mg Injection 1's 114617 PKR 141.68 PKR 141.68/vial/unit 26% below median
Cefmark Ceftriaxone 500 mg Injection 1's 114618 PKR 258.11 PKR 258.11/vial/unit 21% below median
Cefmark Ceftriaxone 1 g Injection 1's 114619 PKR 487.37 PKR 487.37/vial/unit 19% below median
Cin Mark Ciprofloxacin 250 mg Tablet 10's 047084 PKR 240.06 PKR 24.01/tablet 6% below median
Cin-Mark Ciprofloxacin 500 mg Tablet 10's 047085 PKR 332.39 PKR 33.24/tablet 22% below median
Cin-Mark Ciprofloxacin 200 mg/100 mL IV infusion 100ml vial 100409 PKR 184.66 PKR 1.85/mL 20% below median
Cin-Mark Ciprofloxacin 0.3% Ophthalmic drops 5ml 101027 PKR 175.43 PKR 35.09/mL 61% below median
Clodesone Clotrimazole 1% Cream 15gm 101024 PKR 84.94 PKR 5.66/g Near median
Ibu-Mark Ibuprofen 100 mg/5 mL Suspension 90ml 047071 PKR 101.62 PKR 1.13/mL 19% above median
Ibu-Mark Ibuprofen 400 mg Tablet 25x10's 048676 PKR 894.38 PKR 3.58/tablet Near median
IRN-F Iron polymaltose complex 50 mg/5 mL Syrup 60ml 047074 PKR 129.26 PKR 2.15/mL 7% below median
IRN-Fer F Iron polymaltose complex + Folic acid 100 mg elemental iron + 0.35 mg folic acid Tablet 10's 048680 PKR 129.26 PKR 12.93/tablet 9% below median
Liv-Mark Levofloxacin 250 mg Tablet 10's 047079 PKR 461.65 PKR 46.17/tablet Near median
Liv-Mark Levofloxacin 500 mg Tablet 10's 047080 PKR 768.18 PKR 76.82/tablet Near median
Liv-Mark Levofloxacin 500 mg/100 mL IV infusion 100ml vial 100410 PKR 461.65 PKR 4.62/mL 32% below median
Lucimar Loratadine 5 mg/5 mL Suspension 60ml 047073 PKR 90.48 PKR 1.51/mL 24% below median
Lucimar Loratadine 10 mg Tablet 10's 048678 PKR 129.26 PKR 12.93/tablet 10% below median
M-Lusib Injection 1gmRegistry verified Cefoperazone (as sodium), Sulbactam (as sodium) — — — 117942Official source ↗ No indexed price — —
M-Lusib Injection 2gmRegistry verified Cefoperazone ( as sodium) , Salbactam (as sodium) — — — 117941Official source ↗ No indexed price — —
Mark- ctop Clopidogrel 75 mg Tablet 10's 047089 PKR 256.68 PKR 25.67/tablet 6% below median
Markdiaz Silver sulfadiazine 1 % Cream 20gm 101026 PKR 110.80 PKR 5.54/g 57% above median
Markgyl Metronidazole 200 mg/5 mL Suspension 60ml 047077 PKR 59.09 PKR 0.98/mL 9% above median
Markgyl Metronidazole 400 mg Tablet 10x10's 047087 PKR 335.61 PKR 3.36/tablet 13% above median
Markgyl Metronidazole 500 mg/100 mL IV infusion 100ml vial 100411 PKR 189.93 PKR 1.90/mL Near median
Markonza Miconazole 2 % Cream 20gm 101025 PKR 96.02 PKR 4.80/g 37% below median
Markxim Cefotaxime 250 mg Injection 1's 100389 PKR 105.46 PKR 105.46/vial/unit Near median
Markxim Cefotaxime 1 g Injection 1's 100390 PKR 285.88 PKR 285.88/vial/unit Near median
Med-Lecal 5ml Cholecalciferol 5 mg Injection 1mlx5's(Ampoule) 117939 PKR 561.78 PKR 112.36/mL 40% below median
Med-Lecal 5ml Cholecalciferol 5 mg Injection 1mlx1's(Ampoule) 117939 PKR 929.41 PKR 929.41/mL 397% above median
Med-Loratin Losartan 25 mg Tablet 2x10's 116183 PKR 227.19 PKR 11.36/tablet Near median
Med-Loratin Losartan 50 mg Tablet 2x10's 116184 PKR 413.07 PKR 20.65/tablet Near median
Medflix Cephalexin 250 mg Capsule 12's 098925 PKR 188.35 PKR 15.70/capsule Near median
Medflix Cephalexin 500 mg Capsule 12's 098926 PKR 369.32 PKR 30.78/capsule Near median
Medizep Diazepam 5 mg Tablet 30's 061005 PKR 67.12 PKR 2.24/tablet 67% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Medimarker's Laboratories — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/medimarkers-laboratories/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.